Long-Term effects of inhaled budesonide for bronchopulmonary dysplasia

Dirk Bassler, Eric S. Shinwell, Mikko Hallman, Pierre Henri Jarreau, Richard Plavka, Virgilio Carnielli, Christoph Meisner, Corinna Engel, Alexander Koch, Karen Kreutzer, Johannes N. Van Den Anker, Matthias Schwab, Henry L. Halliday, Christian F. Poets

Research output: Contribution to journalArticlepeer-review

102 Scopus citations


BACKGROUND The long-Term effects on neurodevelopment of the use of inhaled glucocorticoids in extremely preterm infants for the prevention or treatment of bronchopulmonary dysplasia are uncertain. METHODS We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to receive early (within 24 hours after birth) inhaled budesonide or placebo. The prespecified secondary long-Term outcome was neurodevelopmental disability among survivors, defined as a composite of cerebral palsy, cognitive delay (a Mental Development Index score of <85 [1 SD below the mean of 100] on the Bayley Scales of Infant Development, Second Edition, with higher scores on the scale indicating better performance), deafness, or blindness at a corrected age of 18 to 22 months. RESULTS Adequate data on the prespecified composite long-Term outcome were available for 629 infants. Of these infants, 148 (48.1%) of 308 infants assigned to budesonide had neurodevelopmental disability, as compared with 165 (51.4%) of 321 infants assigned to placebo (relative risk, adjusted for gestational age, 0.93; 95% confidence interval [CI], 0.80 to 1.09; P = 0.40). There was no significant difference in any of the individual components of the prespecified outcome. There were more deaths in the budesonide group than in the placebo group (82 [19.9%] of 413 infants vs. 58 [14.5%] of 400 infants for whom vital status was available; relative risk, 1.37; 95% CI, 1.01 to 1.86; P = 0.04). CONCLUSIONS Among surviving extremely preterm infants, the rate of neurodevelopmental disability at 2 years did not differ significantly between infants who received early inhaled budesonide for the prevention of bronchopulmonary dysplasia and those who received placebo, but the mortality rate was higher among those who received budesonide. (Funded by the European Union and Chiesi Farmaceutici; ClinicalTrials.gov number, NCT01035190.).

Original languageEnglish
Pages (from-to)148-157
Number of pages10
JournalNew England Journal of Medicine
Issue number2
StatePublished - 11 Jan 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
Copyright © 2018 Massachusetts Medical Society.


Dive into the research topics of 'Long-Term effects of inhaled budesonide for bronchopulmonary dysplasia'. Together they form a unique fingerprint.

Cite this